Dr. Reddy's recalls drugs that failed impurities test

Dr. Reddy's Laboratories plant

Dr. Reddy’s, which already has three plants targeted in a warning letter by the FDA, is now recalling products manufactured at another. 

According to the most recent FDA Enforcement Report, the Indian maker of generic drugs is recalling 50,280 bottles of ondansetron tablets in the U.S. that were manufactured at a facility in Bachupally, India. The report says the tablets, used to prevent nausea and vomiting, failed impurities testing at the 12-month mark. 

Dr. Reddy’s has had several recalls lately, including in February when it retrieved 25,000 bottles of a dialysis drug after getting a host of customer complaints of container leaks. The recalls return the spotlight to the company which last year received FDA warnings for active ingredient plants in Srikakulam and Miryalaguda, as well as its Oncology Formulation manufacturing facility at Duvvada. 

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The agency listed a host of issues at the plants but was particularly ticked off by the discovery that for years the company had what the FDA termed an "uncontrolled Custom QC laboratory" at its plant in Srikakulam. The plant had often shipped products to the U.S. that had repeatedly failed tests for impurities. 

Despite the problems, the company has been able to grow its business in the U.S. On Thursday, it reported that for the year ending March 31, sales in North America were up 19% to Rs 75.4 billion ($1.1 billion), driven by its sterile injectables business. 

- access the FDA Enforcement Report here 
- here's the earnings release 

Related Articles: 
Dr. Reddy's blasted in warning letter for hiding existence of testing lab from FDA 
Dr. Reddy's recalling injected drug manufactured by Gland Pharma 
Dr. Reddy's grows U.S. sales even in face of FDA action


Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.